Table 1

The estimated number of Italian residents to be treated with PZQ according to the screening approach in the 15 top countries of origin

Country, endemicPrevalencea (%)Ref.N of people from the country who are resident in Italy (ISTAT, Jan 2021 census)Total population to treatNumber of doses of Praziquantel neededb (1 day treatment)Number of tabs of Praziquantel neededb (3 days treatment)
Nigeria14.4%3123 64617 80571 220213 660
Senegal31.2% to 39.5%3,4112 59839 803159 212477 636
Ghana38.3%3,447 33518 12972 516217 548
Ivory Coast43.1% to 48%3,428 55913 00952 036156 108
The Gambia23.3%322 637527421 09663 288
Mali63.6% to 72.1%3,421 03214 27057 080171 240
Cameroon24,1%1015 443372114 88444 652
Burkina Faso24,1%1014 204342313 69241 076
Guinea48.8%411 880579723 18869 564
Somalia23.1%393492160864025 920
Eritrea59%116404377815 11245 336
Ethiopia24,1%1064241548619218 576
Total419 511128 717514 8681 544 604
Country, endemicPrevalencea (%)Ref.N of people from the country who are resident in Italy (ISTAT, Jan 2021 census)Total population to treatNumber of doses of Praziquantel neededb (1 day treatment)Number of tabs of Praziquantel neededb (3 days treatment)
Nigeria14.4%3123 64617 80571 220213 660
Senegal31.2% to 39.5%3,4112 59839 803159 212477 636
Ghana38.3%3,447 33518 12972 516217 548
Ivory Coast43.1% to 48%3,428 55913 00952 036156 108
The Gambia23.3%322 637527421 09663 288
Mali63.6% to 72.1%3,421 03214 27057 080171 240
Cameroon24,1%1015 443372114 88444 652
Burkina Faso24,1%1014 204342313 69241 076
Guinea48.8%411 880579723 18869 564
Somalia23.1%393492160864025 920
Eritrea59%116404377815 11245 336
Ethiopia24,1%1064241548619218 576
Total419 511128 717514 8681 544 604

aAll strategies of prevalence measurement were included: serology alone, at least one positive test among serology, CCA point of care and O&P.

bThe number of tablets per person was calculated considering on average 60 kg/person for a dosage of 40 mg/kg (= 4 tablets of 600 mg per person) once or 3-days treatment.

Table 1

The estimated number of Italian residents to be treated with PZQ according to the screening approach in the 15 top countries of origin

Country, endemicPrevalencea (%)Ref.N of people from the country who are resident in Italy (ISTAT, Jan 2021 census)Total population to treatNumber of doses of Praziquantel neededb (1 day treatment)Number of tabs of Praziquantel neededb (3 days treatment)
Nigeria14.4%3123 64617 80571 220213 660
Senegal31.2% to 39.5%3,4112 59839 803159 212477 636
Ghana38.3%3,447 33518 12972 516217 548
Ivory Coast43.1% to 48%3,428 55913 00952 036156 108
The Gambia23.3%322 637527421 09663 288
Mali63.6% to 72.1%3,421 03214 27057 080171 240
Cameroon24,1%1015 443372114 88444 652
Burkina Faso24,1%1014 204342313 69241 076
Guinea48.8%411 880579723 18869 564
Somalia23.1%393492160864025 920
Eritrea59%116404377815 11245 336
Ethiopia24,1%1064241548619218 576
Total419 511128 717514 8681 544 604
Country, endemicPrevalencea (%)Ref.N of people from the country who are resident in Italy (ISTAT, Jan 2021 census)Total population to treatNumber of doses of Praziquantel neededb (1 day treatment)Number of tabs of Praziquantel neededb (3 days treatment)
Nigeria14.4%3123 64617 80571 220213 660
Senegal31.2% to 39.5%3,4112 59839 803159 212477 636
Ghana38.3%3,447 33518 12972 516217 548
Ivory Coast43.1% to 48%3,428 55913 00952 036156 108
The Gambia23.3%322 637527421 09663 288
Mali63.6% to 72.1%3,421 03214 27057 080171 240
Cameroon24,1%1015 443372114 88444 652
Burkina Faso24,1%1014 204342313 69241 076
Guinea48.8%411 880579723 18869 564
Somalia23.1%393492160864025 920
Eritrea59%116404377815 11245 336
Ethiopia24,1%1064241548619218 576
Total419 511128 717514 8681 544 604

aAll strategies of prevalence measurement were included: serology alone, at least one positive test among serology, CCA point of care and O&P.

bThe number of tablets per person was calculated considering on average 60 kg/person for a dosage of 40 mg/kg (= 4 tablets of 600 mg per person) once or 3-days treatment.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close